Rhythm Pharmaceuticals and the Raymond A. Wood Foundation collaborate to study fatigue in craniopharyngioma patients.
Quiver AI Summary
Rhythm Pharmaceuticals, Inc. has announced a collaboration with the Raymond A. Wood Foundation to conduct research on the impact of fatigue in individuals diagnosed with craniopharyngioma, a type of brain tumor. The study aims to gather insights directly from patients and their caregivers to enhance understanding of fatigue's effects and improve patient care. Participants can enroll in the Hypothalamic-Pituitary Brain Tumors Patient Registry to share their experiences, with a focus on factors like weight gain and daytime sleepiness. Both organizations express excitement about the partnership and the potential benefits of the research for improving the quality of life for those affected by the condition.
Potential Positives
- Rhythm Pharmaceuticals has established a significant research collaboration with the Raymond A. Wood Foundation, enhancing its commitment to addressing patient needs in rare neuroendocrine diseases.
- The partnership aims to gather valuable insights related to fatigue in craniopharyngioma patients, which could lead to improved care and treatment outcomes.
- This initiative demonstrates Rhythm's dedication to engaging with patients and caregivers, fostering trust and strengthening community relationships within the patient advocacy space.
Potential Negatives
- The press release heavily emphasizes a research collaboration, which may indicate a lack of established treatment solutions for craniopharyngioma patients and highlight gaps in the company's current offerings.
- The forward-looking statements included suggest uncertainty regarding the potential outcomes of the research collaboration and may raise concerns among investors about the company's ability to deliver on its commitments.
- The mention of risks and uncertainties in the press release, particularly under the forward-looking statements, may create apprehension among stakeholders about the company's future performance and advancements.
FAQ
What is the purpose of the research collaboration between Rhythm Pharmaceuticals and the Raymond A. Wood Foundation?
The collaboration aims to study the impact of fatigue on patients with craniopharyngioma.
Who can participate in the registry study?
Individuals diagnosed with craniopharyngioma and their caregivers are eligible to participate.
How can I enroll in the Hypothalamic-Pituitary Brain Tumors Patient Registry?
You can enroll by visiting www.rawoodfoundation.org/hptumorregistry and completing the available surveys.
What factors are being examined in relation to fatigue for craniopharyngioma survivors?
The study will explore fatigue, weight gain, and daytime sleepiness as factors affecting survivors.
Who should I contact for questions regarding the study?
For questions, you can reach out to registry@rawoodfoundation.org for assistance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RYTM Insider Trading Activity
$RYTM insiders have traded $RYTM stock on the open market 42 times in the past 6 months. Of those trades, 0 have been purchases and 42 have been sales.
Here’s a breakdown of recent trading of $RYTM stock by insiders over the last 6 months:
- JENNIFER KAYDEN LEE (EVP, Head of North America) has made 0 purchases and 17 sales selling 81,645 shares for an estimated $5,301,044.
- JENNIFER L GOOD sold 31,751 shares for an estimated $1,663,803
- JOSEPH SHULMAN (Chief Technical Officer) has made 0 purchases and 9 sales selling 17,053 shares for an estimated $1,100,851.
- DAVID P MEEKER (President and CEO) has made 0 purchases and 2 sales selling 14,174 shares for an estimated $820,490.
- PAMELA J. CRAMER (Chief Human Resources Officer) has made 0 purchases and 6 sales selling 11,960 shares for an estimated $736,050.
- HUNTER C SMITH (Chief Financial Officer) has made 0 purchases and 6 sales selling 5,940 shares for an estimated $343,345.
- CHRISTOPHER PAUL GERMAN (Corporate Controller & CAO) sold 635 shares for an estimated $36,334
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RYTM Hedge Fund Activity
We have seen 104 institutional investors add shares of $RYTM stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC removed 2,067,590 shares (-53.3%) from their portfolio in Q4 2024, for an estimated $115,743,688
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 1,111,043 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $62,196,187
- COMMODORE CAPITAL LP removed 650,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $36,387,000
- PRIMECAP MANAGEMENT CO/CA/ removed 645,721 shares (-8.9%) from their portfolio in Q4 2024, for an estimated $36,147,461
- JANUS HENDERSON GROUP PLC added 621,432 shares (+103.9%) to their portfolio in Q4 2024, for an estimated $34,787,763
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 547,144 shares (-22.6%) from their portfolio in Q4 2024, for an estimated $30,629,121
- NATIONAL BANK OF CANADA /FI/ removed 341,507 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $19,117,561
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RYTM Analyst Ratings
Wall Street analysts have issued reports on $RYTM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 12/31/2024
- Goldman Sachs issued a "Buy" rating on 12/05/2024
- Cowen & Co. issued a "Buy" rating on 11/06/2024
- Guggenheim issued a "Buy" rating on 10/21/2024
To track analyst ratings and price targets for $RYTM, check out Quiver Quantitative's $RYTM forecast page.
$RYTM Price Targets
Multiple analysts have issued price targets for $RYTM recently. We have seen 4 analysts offer price targets for $RYTM in the last 6 months, with a median target of $72.0.
Here are some recent targets:
- An analyst from Stifel Nicolaus set a target price of $78.0 on 03/05/2025
- Dennis Ding from Jefferies set a target price of $80.0 on 01/01/2025
- Corinne Jenkins from Goldman Sachs set a target price of $66.0 on 12/05/2024
- Alan Carr from Needham set a target price of $64.0 on 11/06/2024
Full Release
BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma.
“We are excited to partner with the Raymond A. Wood Foundation on this survey to learn more about fatigue and its effects related to craniopharyngiomas,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “Learning directly from patients and caregivers is important to advancing our understanding of craniopharyngiomas and fatigue and the consequences for improving care for patients.”
All persons who have been diagnosed with craniopharyngioma, or their caregivers, are eligible to participate in this registry study.
“We are pleased to join Rhythm in this effort to better understand craniopharyngioma survivors’ experiences with fatigue and factors that may affect it, such as weight gain and daytime sleepiness,” said Amy Wood, Founder and Executive Director of the Raymond A. Wood Foundation.
To participate in the study, please visit
www.rawoodfoundation.org/hptumorregistry
to enroll into the Hypothalamic-Pituitary Brain Tumors Patient Registry and complete the available surveys. For those who are already enrolled in the registry, please log into your registry account:
https://hptumorregistry.iamrare.org/
.
For questions related to the study, please contact
registry@rawoodfoundation.org
.
About the Raymond A. Wood Foundation
The Raymond A. Wood Foundation is a parent and patient-led rare disease patient advocacy organization, dedicated to empowering survivors of craniopharyngioma and hypothalamic-pituitary brain tumors. The mission of the Raymond A. Wood Foundation is to drive research and advocate for treatment outcomes to improve quality of life for hypothalamic-pituitary brain tumor survivors.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. The Company develops medicines for previously untreatable or undertreated diseases and provides support for healthcare providers and patients and their families. In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in rare melanocortin-4 receptor (MC4R) pathway diseases and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the relationship between craniopharyngiomas and fatigue and the potential benefits of a research collaboration with the Raymond A. Wood Foundation. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties and other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
